Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist medication used to improve glycemic control in adults with type 2 diabetes, in addition to diet and exercise [1]. It's important to be aware of potential drug interactions when using Ozempic with other medications. Here are some considerations based on the available information:

1. Insulin and sulfonylureas: As Ozempic can lower blood sugar levels, using it with other medications that also lower blood sugar, such as insulin or sulfonylureas, may increase the risk of hypoglycemia (low blood sugar) [1]. Therefore, it's crucial to monitor blood glucose levels closely and adjust the dosages of these medications accordingly, under the guidance of a healthcare professional.

2. Oral contraceptives: A study has shown that Ozempic does not affect the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and levonorgestrel [2]. This suggests that Ozempic can be used concomitantly with oral contraceptives without significant drug interactions.

3. Other medications: There is limited information on the interactions of Ozempic with other specific medications. However, it's always advisable to inform healthcare professionals about all medications, supplements, and herbal products being used, as they can provide guidance on potential interactions and appropriate dosage adjustments [1].

In summary, when using Ozempic, it's essential to be aware of potential drug interactions, particularly with insulin and sulfonylureas. Monitoring blood glucose levels closely and adjusting medication dosages under the guidance of a healthcare professional is crucial. Additionally, inform healthcare professionals about all medications, supplements, and herbal products being used to ensure appropriate management of potential drug interactions.

Sources:
[1] FDA. Ozempic (semaglutide) injection, for subcutaneous use [Prescribing Information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208629s000lbl.pdf
[2] Nauck, M., et al. (2016) Effects of once-weekly subcutaneous semaglutide on the pharmacodynamics of an oral contraceptive: A randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism, 18(11), 1115-1122. https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.12742

(Note: DrugPatentWatch.com was not used as a source in this response.)